drug_type
RELEVANT_DRUG
intervention_type
Biologic (mRNA–lipid nanoparticle therapy)
drug_description
An intravenous mRNA–lipid nanoparticle therapy that delivers mRNA to the liver to produce a bispecific T-cell engager targeting GPC3-positive hepatocellular carcinoma cells and activating endogenous T cells for tumor cell killing.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
BISPECIFIC T ENGAGER
drug_class
Gene therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Intravenous lipid nanoparticles deliver mRNA to the liver, where it is translated into a bispecific T-cell engager that binds GPC3 on hepatocellular carcinoma cells and engages endogenous T cells, activating them to mediate cytotoxic killing of GPC3-positive tumor cells.
drug_name
MTS105
nct_id_drug_ref
NCT06689540